ArticleJournal of cachexia, sarcopenia and muscle2026
Selective Small-Molecule AdipoR1 Agonist 3-Hydroxy Pterocarpan Salt (CDRI-1709S) Ameliorates Skeletal Muscle Atrophy.
Article in Journal of cachexia, sarcopenia and muscle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundSkeletal muscle atrophy is a frequent comorbidity of metabolic disorders and chronic diseases, and despite its high prevalence, no pharmacological therapy is available, representing a major unmet clinical need. Adiponectin and its receptors are key regulators of skeletal muscle metabolism, mitochondrial function and myogenesis, yet clinical translation has been hindered by the lack of receptor-selective agonists with favourable pharmacological and safety profiles. Here, we report the identification and characterization of CDRI-1709S, the first small-molecule AdipoR1-selective agonist and evaluate its myogenic and anti-atrophy efficacy.
methodsA PGC-1α luciferase reporter-based screen in AdipoR1/AdipoR2-transfected, AdipoR-low HEK293T cells identified CDRI-1709S as an AdipoR1 agonist. Adiponectin-associated signalling events were evaluated by immunoblotting in AdipoR1/2-overexpressing HEK293T cells and AdipoR-abundant C2C12 myotubes, with receptor specificity confirmed using RNA interference. Myogenic potential was assessed by morphometric analysis and immune detection of myogenic factors. Fibre-type composition and metabolic capacity were evaluated using immunoblotting and extracellular flux analysis. Anti-atrophy effects were examined in vitro using various assault-induced models of myotube atrophy, and in vivo using rat models of dexamethasone (Dex) and sciatic nerve denervation-induced muscle atrophy.
resultsCDRI-1709S selectively activated AdipoR1 with high potency (EC
conclusionCDRI-1709S is the first AdipoR1-selective small-molecule agonist that induced myogenesis and robustly ameliorated skeletal muscle atrophy, establishing the proof-of-concept for AdipoR1-targeting as a promising therapeutic strategy for sarcopenia and skeletal muscle atrophy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.